BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity

BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days

BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days

BMS-986012 (anti-fucosyl-GM1) Intravenous solution once every 3 weeks until disease progression/clinical deterioration or unacceptable toxicity in combination with Nivolumab specified dose on specified days

Number of participants with laboratory abnormalities in specific hepatic tests. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized:

• ALT or AST > 5xULN, > 3xULN, and > 2xULN
• Any of ALT, AST, Total Bilirubin or ALP > 8xULN
• Total bilirubin > 3xULN

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal

BMS-986012 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)).

BMS-986012 area under the serum concentration-time curve in one dosing interval AUC (TAU).

BMS-986012 observed serum concentration at the end of a dosing interval (Ctau).

BMS-986012 total body clearance (CLT).

BMS-986012 trough observed serum concentration (Ctrough).

BMS-986012 Average concentration over a dosing interval ([AUC(TAU)/tau] (Css-avg).

BMS-986012 accumulation index. Ratio of an exposure measure at steady state to that after the first dose.

BMS-986012 Cmax accumulation index (AI_Cmax). Ratio of an exposure measure at steady state to that after the first dose.

BMS-986012 Ctau accumulation index (AI_Ctau). Ratio of an exposure measure at steady state to that after the first dose.

BMS-986012 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure.

BOR defined as the best response designation over the study as a whole. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

ORR is defined as the percent of participants whose BOR is either CR or PR. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

DoR is defined as the time from first response (CR or PR) to the date of the first documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Participants who remain alive and have not progressed will be censored on the date of their last tumor assessment.

Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR )= At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

Median DOR will only be evaluated provided there are enough responding participants to warrant inclusion.

PFS is defined as the time from the date of first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose.

Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

PFSR is defined as the percent of participants who remain progression free and surviving at "t" weeks (t= 12, 24, 36, 48, 60, 72).

Progressive Disease (PD)=At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

Number of participants with anti-BMS-986012 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is a participant with baseline ADA positive sample (Day 1 predose). ADA-positive participant is a participant with at least one ADA positive sample relative to baseline at any time after initiation of treatment during the defined observation time period. ADA negative participant is a participant with no ADA positive sample after the initiation of treatment.

400 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

Total of all reporting groups

400 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

Number of participants with any grade serious adverse events (SAEs). A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:

• results in death
• is life-threatening
• requires inpatient hospitalization or causes prolongation of existing hospitalization
• results in persistent or significant disability/incapacity
• is a congenital anomaly/birth defect
• is an important medical event Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

All treated participants

Number of participants with any grade adverse events (AEs) leading to discontinuation. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

All treated participants

Number of participants who died due to any cause.

All treated participants

Number of participants with laboratory abnormalities in specific hepatic tests. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized:

• ALT or AST > 5xULN, > 3xULN, and > 2xULN
• Any of ALT, AST, Total Bilirubin or ALP > 8xULN
• Total bilirubin > 3xULN

ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ULN = Upper Limit of Normal

All treated participants

BMS-986012 maximum observed serum concentration (Cmax).

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 time of maximum observed serum concentration (Tmax).

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC (0-T)).

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 area under the serum concentration-time curve in one dosing interval AUC (TAU).

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 observed serum concentration at the end of a dosing interval (Ctau).

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 total body clearance (CLT).

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 trough observed serum concentration (Ctrough).

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 Average concentration over a dosing interval ([AUC(TAU)/tau] (Css-avg).

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 accumulation index. Ratio of an exposure measure at steady state to that after the first dose.

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 Cmax accumulation index (AI_Cmax). Ratio of an exposure measure at steady state to that after the first dose.

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 Ctau accumulation index (AI_Ctau). Ratio of an exposure measure at steady state to that after the first dose.

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BMS-986012 effective elimination (T-HALFeff) that explains the degree of accumulation observed for a specific exposure measure.

All participants who receive at least 1 dose of BMS-986012 (and Nivolumab in the combination therapy) and have available serum concentration data for the corresponding analyte

BOR defined as the best response designation over the study as a whole. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD) = Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

All treated participants

ORR is defined as the percent of participants whose BOR is either CR or PR. Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR) = At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

All treated participants

DoR is defined as the time from first response (CR or PR) to the date of the first documented tumor progression as determined using RECIST 1.1 criteria or death due to any cause, whichever occurs first. Participants who remain alive and have not progressed will be censored on the date of their last tumor assessment.

Complete Response (CR) = Disappearance of all target lesions; Partial Response (PR )= At least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

Median DOR will only be evaluated provided there are enough responding participants to warrant inclusion.

Median DoR is pre-specified to only be evaluated provided there are enough responders (CR or PR) to warrant inclusion (Only Cohorts with at least 5 events are analyzed)

PFS is defined as the time from the date of first dose of study medication to the date of the first objective documentation of tumor progression or death due to any cause, if death occurred within 100 days after last BMS-986012 dose.

Progressive Disease (PD) = At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

All treated participants

PFSR is defined as the percent of participants who remain progression free and surviving at "t" weeks (t= 12, 24, 36, 48, 60, 72).

Progressive Disease (PD)=At least a 20% increase in the sum of diameters of target lesions and the sum must demonstrate an absolute increase of at least 5 mm

All treated participants

Number of participants with anti-BMS-986012 antibodies (ADA) with status as baseline ADA positive, ADA positive and ADA negative. Baseline ADA positive participant is a participant with baseline ADA positive sample (Day 1 predose). ADA-positive participant is a participant with at least one ADA positive sample relative to baseline at any time after initiation of treatment during the defined observation time period. ADA negative participant is a participant with no ADA positive sample after the initiation of treatment.

All treated participants who had at least 1 post-treatment immunogenicity assessment

70 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

160 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

160 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

400 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met

1000 mg IV BMS-986012 + 360 mg Nivolumab every 21 days until protocol-specified discontinuation criteria are met